Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease (The Manila Times) - Oct 12, 2026 - "The presentations included longer-term flare protection and safety data from the Phase 3 INDIGO open-label extension, initial findings from an associated vaccine response sub-study, and an analysis of glucocorticoid-associated toxicity from the randomized, controlled period of INDIGO...The 12-month probability of remaining flare-free was 0.93 based upon investigator- and adjudication committee-confirmed flares requiring rescue therapy, and 0.87 based upon investigator-determined flares requiring rescue therapy, with five patients pending adjudication at the time of the data cutoff; The median and mean cumulative glucocorticoid rescue doses were 0 mg and 105 mg, respectively; Adverse event rates were comparable to or lower than those observed during the randomized, controlled period....Fewer patients receiving obexelimab reached clinical thresholds for cumulative glucocorticoid toxicity versus placebo."
P3 data • Immunology • Inflammation
|